Tesamorelin (25mg) Injectable

Improved Lipid Profiles: Tesamorelin has demonstrated positive effects on lipid metabolism, including reductions in triglyceride and LDL cholesterol levels, which helps mitigate cardiovascular disease risk.

Enhanced Cognitive Function: Studies suggest that Tesamorelin can improve memory, focus, and overall cognitive performance. This effect is linked to the increased IGF-1 levels that result from the stimulation of growth hormone release.

Increased Muscle Mass and Physical Performance: Tesamorelin stimulates protein synthesis, leading to enhanced muscle mass and strength. This is particularly beneficial for patients experiencing muscle wasting and for athletes aiming to improve body composition and recovery.

Skin and Cardiovascular Health Benefits: Tesamorelin has been associated with improved skin health, including increased collagen production and reduced wrinkles. Additionally, it may reduce carotid intima-media thickness, a marker of atherosclerosis, suggesting potential cardiovascular benefits.

Metabolic Boost: Tesamorelin increases energy expenditure, improving overall metabolism. romoting fat reduction, particularly in stubborn areas. This effect helps improve body composition and supports weight loss goals by promoting fat reduction, particularly in stubborn areas.

Pregnancy and Breastfeeding: Tesamorelin is contraindicated for pregnant or breastfeeding women due to the lack of established safety in these populations.

Active Cancer: Since Tesamorelin stimulates growth hormone, patients with active cancer should avoid using Tesamorelin unless specifically recommended by a healthcare provider.

Pituitary Gland Disorders: Patients with a history of pituitary gland dysfunction should avoid using Tesamorelin unless specifically recommended by a healthcare provider.

HIV-Associated Lipodystrophy: Tesamorelin is FDA-approved for reducing visceral fat in patients with HIV-associated lipodystrophy, addressing cosmetic and metabolic concerns.

Metabolic Syndrome: Preliminary studies show that Tesamorelin may be beneficial for individuals with metabolic syndrome by improving lipid profiles and reducing visceral fat.

Non-Alcoholic Fatty Liver Disease (NAFLD): Given its effects on fat reduction and metabolic improvement, Tesamorelin has potential in managing NAFLD.

Age-Related Sarcopenia: Tesamorelin may help counteract muscle loss and improve physical strength in elderly zpopulations by promoting protein synthesis.

Cognitive Decline: Emerging research suggests that Tesamorelin may have neuroprotective effects and could be effective as a treatment for conditions like Alzheimer's disease.

Dosing: 1.25 mg = 20 units per injection.

Injections Per Week: 5 injections weekly.

Recommended Cycles: 3 months on (+), 1 month off (-). 3 cycles per year.

Vial Details: 25mg / 4mL

Vial Duration: 4 weeks

Injection Site: Subcutaneous fat on the stomach, thigh, or arm.

Time of Day: Tesamorelin is typically injected in the evening or before bedtime. This aligns with the body's natural peak in growth hormone release during sleep, enhancing effectiveness.

Injection Site Reactions: Common side effects include redness, swelling, or mild discomfort at the injection site, which typically resolve on their own.

Mild Flu-Like Symptoms: Some users report fatigue, headache, or nausea, particularly during initial use.

Muscle and Joint Pain: Some users may experience mild muscle or joint pain, which can become more pronounced in certain cases.

Please contact us if you experience any of the following:
- Fever of 100.4°F (38°C) or higher
- Blistering at the injection site
- Muscle aches, nausea, dizziness, or headache
- Skin rash, severe itching, vomiting, or hives

If you have any questions, please message your healthcare provider through the patient portal or contact us at 646-596-7386.

Start with a Lower Dose: Gradually increase the dose to minimize the risk of side effects;
Rotate Injection Sites: This helps prevent irritation and reduces the risk of injection site reactions.

Take Before Bedtime: Administering the injection before sleep can help align with the body’s natural growth hormone release and reduce unwanted side effects.

Monitor Blood Sugar: Regular monitoring of fasting glucose levels and HbA1c is recommended, especially for individuals with pre-existing glucose intolerance or a history of diabetes.

Consult a Healthcare Provider Regularly: Professional guidance ensures proper dosage adjustments and monitoring of any adverse reactions, which is crucial for safe and effective use.

1-2 Weeks: Improvements in sleep quality and initial reductions in visceral fat are typically noticed.

4-6 Weeks: Significant reductions in abdominal fat and improvements in lipid profiles are often observed by this point. Muscle mass and strength may also begin to improve.

8-12 Weeks: Full benefits, including substantial reductions in visceral fat, enhanced cognitive function, and improvements in body composition, become evident. In a phase III clinical trial, a reduction of up to 15% in visceral adipose tissue was reported in patients with HIV-associated lipodystrophy.

Long-Term: Continuous use of Tesamorelin can lead to sustained improvements in physical performance, reduced cardiovascular risk factors, and enhanced overall quality of life.

Tesamorelin binds to GHRH receptors in the pituitary gland, which in turn stimulates the release of endogenous growth hormone. This increase in GH production results in elevated levels of insulin-like growth factor 1 (IGF-1), which plays a crucial role in promoting lipolysis (fat breakdown), protein synthesis, and muscle growth. This mechanism makes Tesamorelin particularly effective in reducing visceral adipose tissue and improving overall body composition. It also enhances metabolic functions by modulating lipid metabolism and insulin sensitivity.